MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

Impact · against what's priced in

The publication of preclinical data for MiNK-215 provides technical validation for a novel approach to dismantling tumor stroma in solid tumors. As this is early-stage preclinical evidence for a next-generation asset, it serves as a fundamental proof-of-concept that expands the company's long-term valuation potential.

INKT+0.50

No priced-in read yet